In the past decade, positron emission tomography (PET) has been established as an important diagnostic tool in the management of gliomas. 15 In our initial published study, we demonstrated that the intratumoral uptake of the radiolabeled amino acid O-(2-[ 18 F]-fluoroethyl)-L-tyrosine ( 18 F-FET) over time (aka "time activity curves" [TACs] ) can be characterized by 3 distinct patterns in Gd-negative tumors: (i) a homogeneously increasing, (ii) a homogeneously decreasing, and (iii) a mixed pattern with both increasing and decreasing TACs within the same tumor. 16 In our recently published follow-up evaluation, we found associations between TAC patterns and progression-free survival (PFS): homogeneous increasing TAC tumors experienced favorable PFS and those with decreasing TAC significantly worse PFS. 17 However, no significant PFS difference was seen between mixed and homogeneous decreasing TAC tumors and no valid death rate estimation was possible due to the short follow-up period. Thus, the place of the reported 3-scaled TAC pattern in prognostic models of Gd-negative gliomas still needs elucidation. For clarification the current long-term analysis was conducted. We here analyzed the prognostic impact of TAC within the framework of the molecular markers implemented in the 2016 revision of the World Health Organization (WHO) classification scheme for brain tumors. 5 As recently published studies have pointed to the prognostic importance of quantitative TAC analyses, 18, 19 we did additionally post-hoc quantitative analyses of TAC in terms of minimal time-topeak (TTP min ) measurements to elucidate and compare the strengths, similarities, and differences of qualitative and quantitative TAC data in prognostic models of Gd-negative gliomas. We further assessed the usefulness of TAC-defined targets for surgical guidance and did post-hoc analyses on the efficacy of treatment strategies among patients exhibiting the same/distinct TAC patterns.
Methods

Patients
The design of this prospective single center study has been described in detail before. 16, 17 In brief, patients with MRI-suspected Gd-negative low-grade glioma exhibiting increased 18 F-FET uptake (compared with the corresponding area in the non-affected contralateral hemisphere) were included. MRI-suspected low-grade gliomas were defined as hyperintense (hypointense) Gd-negative lesions in T 2 (T 1 )-weighted sequences exhibiting space occupying effects. Patients were enrolled between February 2006 and September 2010. Informed consent was obtained from all patients. The study protocol was reviewed and approved by the ethical review board of the Ludwig-Maximilians University in Munich, Germany (AZ 216/14).
F-FET-PET Protocol
A detailed description has been presented before. 17 In brief, an ECAT EXACT HR+ scanner (Siemens Healthineers) was used in all patients. Following a 15 min transmission scan (germanium-68 rotating rod source), a 40 min long dynamic emission recording in 3D mode was started immediately after intravenous bolus injection of approximately 180 MBq 18 F-FET. PET data were reconstructed by filtered back projection and corrected for attenuation, scatter, random, and dead time. Dynamic PET data were acquired using predefined time frames (7 × 10 s, 3 × 30 s, 1 × 2 min, 3 × 5 min, 2 × 10 min). Spatial resolution of 18 F-FET PET was 2.0 mm × 2.0 mm × 1.0 mm per pixel with a centercenter separation of 1.2 pixel. PET data were routinely coregistered with MRI and evaluated at the work station (Hermes Medical Solutions). Investigators were blinded for clinical, histological, and molecular data. Maximal 18 F-FET uptakes within the tumor (expressed as maximal standardized uptake value [SUV max ]) were determined on late summation images (20-40 min post-tracer injection [p.i.]), and maximal tumor to mean background (BG) ratios (SUV max / BG) were calculated. For dynamic analyses the early summation image (10-30 min p.i.) were used for the definition of a 90% isocontour threshold region of interest (ROI). Subsequently, these ROIs were applied to the corresponding slices of the entire dynamic PET images to extract individual TACs for the kinetic analysis in a slice-by-slice manner. Each TAC within the slice-by-slice analyses during the 40 min time interval after tracer injection was defined as follows: (i) increasing TAC with SUV constantly ascending or reaching a peak followed by a plateau in the subsequent frames (±3% of the peak SUV) and (ii) decreasing TAC with SUV showing an early peak followed by a constant descent thereafter. Early fluctuations in the TACs within the first short time frames (7 × 10 s followed by 3 × 30 s) representing noise were excluded from kinetic analyses. Each tumor was mapped per its intratumoral TAC patterns: Tumors with increasing TAC in all slices throughout the
Importance of the study
The prognosis of Gd-negative gliomas varies widely and is determined by histopathology and molecular-genetic profiles. The current study indicates that advanced imaging techniques such as dynamic 18 F-FET-PET can provide prognostic information independent of WHO grade and IDH mutational status. Adjusted and unadjusted survival estimates relying either on WHO grade and IDH mutational status or alternatively on TACs of dynamic 18 F-FET-PET resulted in a 3-scaled outcome pattern, which was well matched across the models. Our data provide evidence of dynamic 18 F-FET-PET as a prognostic imaging biomarker. Our findings open new avenues for patient counseling and treatment planning.
whole tumor were classified as having homogeneously increasing kinetics, tumors with decreasing TAC in all slices throughout the whole tumor were considered as having homogeneously decreasing kinetics, and tumors with both increasing and decreasing TAC slices were classified as having a mixed TAC pattern. The prospectively performed qualitative categorization of TAC was supplemented by blinded, post-hoc quantitative TAC analyses in terms of TTP min measurements. Both the initial qualitative and the post-hoc quantitative TAC analyses were done by 2 experienced nuclear physicians. In case of different findings, a conference was initiated in order to reach consensus. For each patient included in this study, TTP was assessed in each slice throughout the whole tumor; consequently, the shortest TTP in at least 2 consecutive slices was defined as TTP min as previously published. 20 To estimate the approximate volume of focal decreasing TAC (hot spot) in heterogeneously composed tumors, areas showing decreasing TAC were segmented in each individual slice on the static PET images by means of a semiautomatic threshold-based calculation (SUV/ BG ≥ 1.8). For further biopsy planning, the center of the hot spot was labeled in the corresponding PET data by means of a 9 × 9 mm square marker.
PET-Guided Stereotactic Biopsy Protocol
At the time of the initial presentation, all patients underwent 18 F-FET-PET-guided serial stereotactic biopsy procedures, as described previously. 16, 21 Trajectory planning was based on coregistered multimodal imaging data including computed tomography (CT), MRI, and 3D dynamic 18 F-FET uptake data (i-plan stereotaxy, Brainlab). The applied MRI protocol has been described previously. 16 Serial biopsy samples (1 mm 3 in size) were collected in 1 mm steps along the trajectory for representative tissue sampling. Tumor samples were collected from areas exhibiting the same/different 18 F-FET uptake kinetics (eg, "hot spots" with decreasing TAC embedded within tumor areas with increasing TAC). Histopathological examination was done in a blinded fashion unaware of the PET findings. Samples selected for histological examination were paraffin embedded, whereas for molecular-genetic analyses at least 2 snap-frozen samples were used. Each of the collected samples was tagged according to its exact location within the stereotactically localized 3D imaging matrix, allowing correlative analyses between areas of similar/different histopathological and molecular-genetic findings and their corresponding TAC patterns.
Histology and Molecular Markers
All patients were grouped according to histopathology and molecular profiles as being recommended by the 2016 WHO classification of brain tumors. 5 IDH-mutational status was determined by pyrosequencing, 1p/19q codeletion status by microsatellite analysis, and O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation status by methylation-specific PCR and bisulfite sequencing. In addition, the telomerase reverse transcriptase (TERT) mutational status was determined in IDH-wildtype tumors by PCR and sequencing. 21 
Patient Management
All treatment decisions were made by the interdisciplinary tumor board under consideration of patient-and tumorrelated covariates (eg, Karnofsky performance status [KPS], tumor location, histological diagnosis, the molecular biomarker profile). PET data were not part of the standardized treatment algorithm. Circumscribed tumors were generally considered for open tumor resection or alternatively (in case of small sized and complex located gliomas) for stereotactic brachytherapy. 22 WHO grade II gliomas with diffuse extensions and/or functionally eloquent locations exhibiting favorable molecular profiles (ie, 1p/19q codeletion) and all IDH-mutant WHO grade III gliomas usually underwent upfront chemotherapy rather than radiation therapy. 23 IDH-wildtype anaplastic gliomas and all WHO grade IV glioblastomas were commonly treated with radiotherapy plus concomitant and adjuvant temozolomide. 24, 25 In selected clinically asymptomatic patients with IDH-mutant and occasionally 1p/19q codeleted grade II gliomas, treatment was withheld and a wait-and-scan attitude preferred. 26 Treatment response was evaluated according to contemporary guidelines at the time of patient enrollment. 12, 27 For the sake of objective comparability, all MRI scans have been reevaluated according to current Response Assessment in Neuro-Oncology criteria. 12 Before initiation of salvage treatment, a re-biopsy was done for verification of tumor progression. In case of an assumed pseudoprogression after chemotherapy/radiotherapy, another 18 F-FET-PET examination was performed. 28, 29 Recommendations for salvage treatment were given by the interdisciplinary tumor board.
Statistical Analysis
The reference point for this study was the date of initial stereotactic biopsy. Date of last follow-up was July 2017. The sample size of our initial intermediate-term analysis was based on the presumption of an unadjusted hazard ratio of at least 2 for any form of decreasing TAC to be associated with tumor progression. In the current longterm analysis, we presumed an unadjusted hazard ratio of at least 2 for any form of decreasing TAC to be associated with death. Given an accrual period of 48 months and a total time of 139 months, a sample size of at least 36 tumors in each of the 2 TAC groups (increasing vs decreasing) would be also sufficient to support/reject the study hypothesis with a statistic power of 80%. Progression-free survival, overall survival (OS), and post-recurrence survival (PRS) were analyzed with the Kaplan-Meier method and compared with the log-rank statistic. Prognostic factors were obtained from univariate and multivariate proportional hazards models. First, the importance of each variable was tested univariately. Second, all variables were fitted together. The final models contained only variables associated with PFS, OS, or PRS after adjustment for the effects of the other variables. In case of intercorrelated
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covariates, alternative models with inclusion of either of these covariates were tested and compared by computing the maximized likelihoods. Adjusted survival curves were computed to demonstrate the prognostic impact of the selected covariates. Logistic regression models were used to elucidate the association of TACs with biospecimenderived and clinically derived biomarkers. The distribution of continuously scaled variables was analyzed with the Wilcoxon test. For dichotomized variables, the chi-squared statistics or Fisher's exact test (in case of small sample sizes) was used. All calculations were performed using SAS software v9.2. Median follow-up of the survivors was 90 months (range, 32-132 mo). Seventy-nine (80.6%) patients experienced tumor progression and 50 (51.0%) patients died. Twenty out of 52 IDH-mutant grade II patients suffered from tumor progression with biopsy-proven malignant transformation (toward WHO grades III/IV histology). In 13 of these patients, a follow-up 18 F-FET-PET was available at the time of malignant transformation, indicating a corresponding shift in qualitative (quantitative) TAC measurements from an initially homogeneous increasing TAC (long TTP min ) toward a mixed TAC pattern (intermediate TTP min ) in 9 and toward a homogeneous decreasing TAC pattern (short TTP min ) in 4 tumors. Overall, median PFS, OS, and PRS of the study population were 40 months (95% CI: 28-52 mo), 84 months (95% CI: 51-117), and 20 months (95% CI: 8-32), respectively.
Results
Overall
Prognostic Models
A compilation of the results of univariate and multivariate analyses for PFS, OS, and PRS is shown in Table 2 . Multivariately, outcome could be similarly precisely predicted by a biospecimen-derived and the 2 imaging-derived models including either qualitative TAC assessment or quantitative TTP min measurements: In the multivariate biospecimen-derived model WHO grade (II vs III/IV, P < 0.0001) and IDH-mutational status (P < 0.001) were independently associated with PFS and OS. In the 2 alternative imagingderived multivariate models, the 1p/19q codeletion status (P < 0.01) and either TAC patterns (P < 0.0001) or the 3-scaled TTP min classifier (P < 0.0001) turned out to be significant predictors for PFS and OS. The unadjusted hazard ratio of any form of decreasing TAC for tumor progression and death was 3.4 (95% CI: 2.17-5.6) and 5.5 (95% CI: 2.8-10.6), respectively. For the 3-scaled TAC classifier, we found a stepwise risk increase of 1.8 (95% CI: 1.36-2.3) for tumor progression and 1.9 (95% CI: 1.39-2.6) for death. Similar risk estimations could be obtained from TTP min measurements (see Table 2 ). In univariable analyses, the impact of TTP min on PFS was even more powerful than qualitative TAC assessment. Sensitivity, specificity, and positive predictive value of the homogeneous increasing and the mixed TAC patterns to detect an IDH-mutant glioma (grade II or III) was 94.2%, 83.0%, and 93.0%, respectively. The corresponding values for the late and intermediate TTP min classes were 91.3%, 76%, and 90%. The difference was statistically not significant (P = 0.9). Overall, both kinetic classification schemes were highly intercorrelated (P < 0.0001). IDH-wildtype, TERT positive, grade II gliomas (n = 5) were found in each of the TAC groups and exhibited also variable TTP min Codel., codeletion; pos., positive; neg., negative; CTx, chemotherapy; RTx, radiotherapy; SBT, stereotactic brachytherapy; Surg, microsurgical resection. In multivariate logistic regression analysis, a WHO grades III/IV tumor was associated with decreasing TAC (P < 0.0001). An alternative model with inclusion of TTP min measurements indicated IDH-wildtype status (P < 0.001) and WHO grades III/IV (P < 0.01) independently to be associated with a TTP min ≤ 12.5 min.
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Treatment
Initial and salvage treatment concepts are summarized in Table 1 and the Supplementary Table. Early radiotherapy and/or chemotherapy were more frequently applied in the mixed and the homogeneous decreasing TAC groups (P < 0.001), whereas localized treatment strategies only (such as resection or brachytherapy) were preferred for circumscribed homogeneous increasing TAC tumors (P = 0.03). Within each TAC group the applied treatment (localized vs irradiation and/or chemotherapy) regimen did not gain prognostic impact.
Nineteen patients with IDH-mutant grade II gliomas underwent careful observation (89.5% of these patients exhibited an increasing TAC pattern/long TTP min ). Associated PFS tended to be shorter than for the corresponding early treatment group (median PFS, 37 mo [95% CI: 22-52 mo] vs 70 months [95% CI: 59-81 mo]; P = 0.07). However, delayed radio-and/or chemotherapy at the time of tumor progression was associated with longer PRS in the wait-and-scan group (median PRS: 41 mo [95% CI: not reached] vs 29 months [95% CI: 11-46 mo]; P = 0.05), resulting in comparable OS in both the early and delayed treatment groups (Table 1) .
Discussion
18 F-FET-PET data processing including TAC analysis has been shown to be a rather robust and reproducible method for glioma grading. 20 Using 18 F-FET-PET-guided serial stereotactic molecular biopsy technique we recently described 3 intratumoral TAC patterns in Gd-negative gliomas, each correlating with distinct histopathological and molecular-genetic profiles. 16, 17 This is to our knowledge the first prospective sufficiently powered long-term study analyzing the risk of death in Gd-negative gliomas stratified for TAC patterns, WHO grade, and molecular biomarker profiles. We found an approximately 5-fold increased unadjusted risk of death in case of any form of decreasing TAC compared with homogeneous increasing TAC tumors. Our data indicate additionally that in qualitative TAC analysis, not only the separation between increasing and decreasing TAC but also the consideration of their spatial distribution (ie, mixed TAC patterns) within the tumor landscape matter for prognostic evaluation resulting in the 3-scaled TAC pattern-based prognostic classifier of this study.
As some studies have pointed to the prognostic impact of TTP min measurements in glioma, we additionally performed post-hoc analyses of TTP min of each tumor. 18 We found 3-scaled qualitative TAC and quantitative TTP min measurements to be highly intercorrelated. Homogeneous 
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decreasing TAC (homogeneous increasing TAC) tumors experienced the shortest (longest) median TTP min measurements. Median TTP min of mixed TAC tumors was in between. Similar to the 3-scaled qualitative classifier, the distribution of the TTP min values also allowed a 3-scaled stratification (>25 min vs >12.5 min and ≤25 min vs ≤12.5 min) of the study population. We here tested and compared the usefulness of this new quantitative retrospectively obtained TTP min classifier with the qualitative TAC data.
We demonstrate that models relying either on nuclear imaging-derived (qualitatively obtained 3-scaled TAC pattern/3-scaled TTP min classification) or biospecimenderived biomarkers predicted nearly identical survival rates. Homogeneous increasing TAC tumors and those gliomas exhibiting a TTP min > 25 min did as well as IDH-mutant grade II gliomas and those gliomas with homogeneous decreasing TAC/TTP min ≤ 12.5 min as poor as IDH-wildtype tumors. IDH-mutant grade III, mixed TAC tumors and those exhibiting a TTP min between 12.5 and 25.0 min had an intermediate prognosis. Whereas a 1p/19q codeletion was not considered in the biospecimen-derived prognostic model (probably because of the relatively small sample size of codeleted tumors), it gained influence in both kinetic models. It cannot be excluded, however, that the impact of the 1p/19q status was overestimated in the imaging-derived models and was triggered mainly by some grade II oligodendrogliomas with favorable outcome scores resembling found within the decreasing (short/intermediate) TAC (TTP min ) group. Limitations of TAC analyses in grade II oligodendrogliomas have already been reported in the literature and have become apparent also in this study for TTP min measurements. 30 Only a few tumors did not fit the Fig. 1 Kaplan-Meier curves of overall survival for the entire study population stratified by WHO grade and molecular-genetic markers according to the new 2016 WHO classification scheme (A), TAC patterns (B) and TTP min analysis (C). Significant differences in OS were shown in each of the 3-scaled curves.
described correlation schemes. Beyond the 1p/19q codeleted tumors, IDH-wildtype tumors with/without an additional TERT mutation were not unequivocally characterized as malignant gliomas. Apparently these lesions experienced heterogeneous tumor characteristics, which cannot be unequivocally classified by both qualitative and quantitative TAC analyses. More data are necessary to elucidate whether TAC analyses might provide additional information relevant for prognosis of these rather rare grade II glioma subpopulations. 6 Notably, the detected powerful impact of the 3-scaled TTP min classes derived from retrospective analyses and must therefore be interpreted cautiously. Further prospective evaluation is needed. We demonstrated further that IDH-mutant tumors experienced longer TTP min times, which was independent of tumor grade. Other studies have already reported a similar correlation but did not adjust their findings for the effects of tumor grade. 18, 31 Whereas a higher tumor grade turned out to be the main determinant for the evolvement of a decreasing TAC pattern, TTP min measurements seem to be more sensitive to identify differences among decreasing TACs of distinct tumors not recognizable by qualitative TAC analyses. Longer TTP min times in IDH-mutant grade III tumors might point to less aggressiveness of these tumors compared with their IDH-wildtype counterparts. It will be a matter of further research to elucidate correlations between the IDH mutational status, the expression of the L-system amino acid transporter (LAT) in tumor vessels, as well as microvessel density (which can be seen in malignant gliomas as well as sometimes in grade II oligodendrogliomas). All these factors are increasingly considered important for both rapid influx and early wash-out effects of 18 F-FET in glioma. [32] [33] [34] [35] [36] Mixed TAC tumors, which experienced an intermediate prognosis in this series, represent the diagnostically most challenging subgroup among the Gd-negative tumors. These tumors might be easily misclassified as WHO grade II gliomas in case of non-representative resection/biopsy strategies resulting in undertreatment and potential worsening of the overall prognosis. Thus, initial characterization of the Gd-negative gliomas by molecular imaging such as 18 F-FET-PET is indispensable to identify these heterogeneously composed tumors and to guide biopsy/resection for representative tissue sampling either initially at the time of the first presentation or when tumor progression is assumed. According to our data, homogeneous increasing TAC tumors could evolve to mixed TAC or even homogeneous decreasing TAC tumors during the tumor progression process, which was always associated with biopsy-proven malignant transformation. 29, 37 These changes also became evident in quantitative TAC analyses, indicating a shift from long TTP min to the intermediate or short TTP min values.
Given the strong correlation between the biospecimenderived and imaging-derived models, it was not surprising that TAC patterns and treatment were highly intercorrelated. Patients with mixed (intermediate TTP min ) or homogeneous decreasing TAC (short TTP min ) patterns received the most dense treatment protocols, whereas patients undergoing localized treatment or even a wait-and-scan attitude typically belonged to the homogeneous increasing TAC/long TTP min group. The depiction of increasing TAC tumors either as circumscribed or diffuse might support treatment decisions in favor of a more or less localized therapy, thereby in the future possibly improving the risk/benefit profile of the applied treatment. This hypothesis needs further prospective evaluation. 
A considerable number of patients mainly with homogeneous increasing TAC (long TTP min ) tumors received delayed treatment. This patient subpopulation had smaller tumor volumes and no/minimal clinical deficits and was younger compared with those undergoing early treatment. PFS was shorter after wait-and-scan. This disadvantage, however, was compensated by longer PRS after delayed treatment, resulting in similarly long survival in the early and delayed treatment groups. This new finding should be prospectively evaluated. Our data suggest that in highly selected asymptomatic patients <40 years of age (most likely excluding IDH-wildtype, TERT positive tumors) with supratentorial, unresectable, homogeneous increasing TAC/long TTP min tumors, biopsy should be performed but treatment may be withheld until tumor progression occurs.
Conclusion
The prognosis of Gd-negative gliomas can be described by qualitative and probably similarly precisely also by quantitative TAC assessment without knowledge of tumor grade and IDH mutational status. Limitations of the respective TAC models concerned low-grade oligodendrogliomas (sometimes classified as malignant gliomas) and IDHwildtype, TERT positive grade II astrocytomas (sometimes described by a favorable kinetic pattern). TAC analyses provide the possibility to guide biopsy and resection particularly in heterogeneously composed tumors. It enables further adjustment of invasiveness, time point of diagnostic procedures, and treatment to the metabolic profile of the tumor under consideration.
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